Blinded Bevacizumab

Role

Indications

Reactions

Primary

Drug Use For Unknown Indication	26.1%
Breast Cancer	21.1%
Diffuse Large B-cell Lymphoma	20.4%
Glioblastoma	5.4%
Breast Cancer Metastatic	5.3%
Prostate Cancer	3.6%
Ovarian Cancer	3.4%
Metastatic Malignant Melanoma	2.9%
Gastric Cancer	2.4%
Glioblastoma Multiforme	2.4%
Ovarian Epithelial Cancer	2.0%
Non-small Cell Lung Cancer	1.1%
Neoplasm Malignant	0.7%
Transitional Cell Carcinoma	0.7%
Fallopian Tube Cancer	0.6%
Metastatic Gastric Cancer	0.5%
Constipation	0.3%
Neuropathy Peripheral	0.3%
Ovarian Cancer Metastatic	0.3%
Pancreatic Carcinoma Metastatic	0.3%

Pyrexia	15.1%
Convulsion	14.0%
Anaemia	7.0%
Sepsis	7.0%
Small Intestinal Obstruction	7.0%
Sudden Death	4.7%
Vomiting	4.7%
Chest Pain	3.5%
Haemoglobin Decreased	3.5%
Peripheral Sensory Neuropathy	3.5%
Platelet Count Decreased	3.5%
Pneumonia	3.5%
Pneumonitis	3.5%
Pulmonary Oedema	3.5%
Splenic Abscess	3.5%
Thrombosis	3.5%
Acute Respiratory Distress Syndrome	2.3%
Atrial Fibrillation	2.3%
Bacteraemia	2.3%
Cerebral Ischaemia	2.3%

Secondary

Diffuse Large B-cell Lymphoma	50.4%
Drug Use For Unknown Indication	28.6%
Product Used For Unknown Indication	4.7%
Gastric Cancer	4.2%
Non-hodgkin's Lymphoma	2.6%
Breast Cancer Metastatic	2.0%
B-cell Lymphoma	1.8%
Breast Cancer	1.7%
Non-small Cell Lung Cancer	0.8%
Colorectal Cancer Metastatic	0.6%
Lymphoma	0.6%
Metastatic Renal Cell Carcinoma	0.5%
Metastatic Gastric Cancer	0.4%
Glioblastoma	0.2%
Multiple Myeloma	0.2%
Nausea	0.1%
Pain	0.1%
Premedication	0.1%
Glioblastoma Multiforme	0.1%
Hodgkin's Disease	0.1%

Febrile Neutropenia	35.9%
Neutropenia	8.6%
Pneumonia Aspiration	7.3%
Pyrexia	4.7%
Pneumonia	4.2%
Pulmonary Embolism	4.2%
Respiratory Failure	4.2%
Mucosal Inflammation	3.3%
Septic Shock	3.3%
White Blood Cell Count Decreased	3.1%
Gastric Perforation	2.9%
Upper Gastrointestinal Haemorrhage	2.9%
Hypokalaemia	2.2%
Rectal Ulcer	2.2%
Ascites	2.0%
Stomatitis	2.0%
Blood Sodium Decreased	1.8%
Convulsion	1.8%
Neutropenic Sepsis	1.8%
Laboratory Test Abnormal	1.6%